GSK to acquire Aiolos Bio for US$ 1 billion upfront payment
Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway
Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway
The congress aims at emphasizing on the most recent trends, advancements in the field of Obstetrics & Gynaecology
The company has received five final approvals
The company received gross proceeds of approximately US$1.7 million and net proceeds,
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering
Marks remarkable acceleration in innovation using AI technology
This combination aims to offer an effective tool to manage symptoms of nausea and vomiting during pregnancy
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
Subscribe To Our Newsletter & Stay Updated